Start-Up Spotlight: Distalmotion Wants To Bring Cost-Effective, Focused Alternative To Robotic Surgery Market
Switzerland-based Distalmotion hopes to make its Dexter robotic surgery the standard of care in procedures that entail precise dissection and suturing and market itself as a more cost-effective alternative to Intuitive Surgical’s da Vinci system.
You may also be interested in...
Robot’s surgeon or surgeon’s robot? Swiss innovator Distalmotion is pressing ahead with the latter approach having added new directors, and new funding and commercial scale-up resources to further the global vision for its laparoscopic-robotic surgery tool with a difference.
Robotics means different things to different surgeons, according to Swiss innovator Distalmotion, whose surgical robot combines with laparoscopy to leave the surgeon fully in control in the OR.
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.